Abstract
In adoptive immunotherapy, the number of effector cells is one of the major factors relating to the therapeutic efficacy. We demonstrated that tumor-infiltrating lymphocytes (TILs) were stimulated to proliferate by incubation with interleukin 2 (IL-2) plus interleukin 4 (IL-4). TILs cultured with IL-2 plus IL-4 increased 3.1-fold more than TILs cultured with IL-2 alone. However, IL-4 did not alter the cytotoxic activity of TILs against autologous tumor cells and established tumor cell lines. It is suggested that IL-2 receptor is related to the mechanism of the proliferation of activated TILs cultured by combination with IL-2 and IL-4. Thus, the combination of IL-2 and IL-4 may increase the efficacy of adoptive immunotherapy using activated TILs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AIT:
-
adoptive immunotherapy
- CTL:
-
cytotoxic T lymphocytes
- IL-4:
-
interleukin 4
- IL-2:
-
interleukin 2
- LAK:
-
lymphokine-activated killer
- TILs:
-
tumor-infiltrating lymphocytes
References
Noma Y, Sideras P, Naito T, Bergstedt-Lindquist S, Azuma C, Severinson E, Tanabe T, Kinashi T, Matsuda F, Yaoita Y, Honjo T. Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature 1986; 319: 640–6.
Swain SL, Howard M, Kappler J, Marrack P, Watson J, Booth R, Wetzel GD, Dutton RW. Evidence for two distinct of murine B cell growth factor with activities in different functional assays. J Exp Med 1983; 158: 822–35.
Lee F, Tokota T, Otsuka T, Meyerson P, Villaret D, Coffman R, Mosmann T, Rennick D, Rothm N, Smith C, Zlotnik A, Arai K. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell- and mast-cell-stimulating activities. Proc Natl Acad Sci 1986; 83: 2061–5.
Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T, Paul WE. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 1982; 155: 914–23.
Mule JJ, Smith CA, Rosenberg SA. Interleukin 4 (B cell stimulatory factor 1) can mediated the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med 1987; 166: 792–7.
Nagler A, Lanier LL, Phillips JH. The effects of IL-4 on human natural killer cells. J Immunol 1988; 141: 2349–51.
Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988; 168: 2183–91.
Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanoma. Cancer Res 1986; 46: 3011–7.
Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Tamai M, Inoue M. Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy 1990; 2: 247–59.
Maeda M, Noma T, Hama K, Honjo T. Application of a human T cell line derived from a Sezary syndrome patient for human interleukin 4 assay. Immunol Letters 1988; 18: 247–54.
Fujii M, Sugamura K, Sano K, Nakai M, Sugita K, Hinuma Y. High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J Exp Med 1986; 163: 550–62.
Rosenberg SA, Spiess PM, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–21.
Fernandez-Botran R, Sanders VM, Vitetta ES. Interactions between receptors for interleukin 2 and interleukin 4 on lines of helper T cells (HT-2) and B lymphoma cells (BCL1). J Exp Med 1989; 169: 379–91.
Tigges MA, Casey LS, Koshland ME. Mechanism of interleukin-2 signaling: mediation of different outcomes by a single receptor and transduction pathway. Science 1989; 243: 781–6.
Higuchi CM, Thompson JA, Lindgren CG, Gillis S, Widmer MB, Kern DE, Fefer A. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2in vivo orin vitro. Cancer Res 1989; 49: 6487–92.
Trenn G, Takayama H, Hu-Li J, Sitkovsky MV. B cell stimulatory factor 1 (IL-4) enhances the development of cytotoxic T cells from Lyt-2+ resting murine T lymphocytes. J Immunol 1988; 140: 1101–6.
Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CTAS). J Immunol 1989; 142: 800–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsunoda, T., Tanimura, H., Yamaue, H. et al. The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor. Biotherapy 4, 9–15 (1992). https://doi.org/10.1007/BF02171704
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02171704